X
Archive by author: Lindsey HoughtonReturn
After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.Read all about it on the C...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA testing and has been approved by the US FDA for WNV, ZIKA, and now Ultrio Elite testing. The Procleix Panther instrument with its automated process will allow the CTS laboratories to operate with increased efficiencies with processing all three assays (WNV, ZIKA, Ultrio Elite) using a single pooled or individual donation sample. We expect less downtime and fewer NAT assay failures. On Tu...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about many questions as hospitals and blood centers prepare to order the testing. We've put together a FAQ document to clarify what we know today. We will update the document as we get more information on existing questions and as new questions get asked, and will update the blog with the revised FAQ document.Thanks for your support as we work to rapidly get this testing available to you. &nbs...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects antibody (including IgG and IgM) to SARS-CoV-2 S protein on April 20, 2020. Additionally, Vitalant Research Institute is offering the SARS-CoV-2 Reporter Viral Particle Neutralization (RVPN) test.The situation is rapidly developing and we know you likely have many questions, but you can find all the current information here: 
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV, and HCV), performed on the Tigris testing platform, to the newer Ultrio Elite triplex assay, and performed on the Panther testing platform. The CTS Phoenix lab will implement first on July 7th, with the 4 remaining CTS labs located in Charlotte, Dallas, St. Louis amd Tampa all implementing on July 13, 2020. Click here for all the details:
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive test result files, due to the old sFTP server needing to be decommissioned.Get the details here:Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ultrio Assay to the Grifols Procleix Ultrio Elite Assay on the fully automated Panther System.Read all about it on the Communication page by clicking the this link:Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.Read about our plan to mitigate this on the Communications page by clicking this link: Communications&l...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols  Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.Check out the Communication page for the complete details by clicking the link:
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus; Guidance for Industry” was released on October 2, 2019 and recommends that CTS modify our current HCV reflex testing algorithm to support these best practices. The new algorithm will take effect on April 20, 2020.Check out the Communication page for the complete details by clicking the link:

Subscribe here to receive CTS updates!

Name